SLC5A2 and hepatocellular carcinoma: Their multifaceted mechanisms, including anti-inflammatory and diuretic effects, position them as potential therapeutic agents for liver disease beyond glycemic control. While preclinical and clinical evidence highlights the potential benefits of SGLT2 inhibitors in cirrhosis-related complications such as ascites, HCC, and possibly HRS, caution is necessary due to limited data and the risk of adverse effects, such as acute kidney injury and infections.